×

Presenter

Peter Foley

Skin Health Institute

Associate Professor Peter Foley (MBBS, BMedSc, FACD)

Associate Professor Foley’s interests in dermatology include psoriasis, photosensitivity (sunlight sensitivity) disorders, non surgical management of nonmelanoma skin cancers and photodynamic therapy (PDT). He was one of the first doctors in Australia to introduce PDT, being involved with clinical trials with this treatment option from 2001. Currently he is on the Board of Directors of the International Society for Photodynamic Therapy in Dermatology and on the editorial board of Clinical Photodynamics in Dermatology. He is Australia’s only councillor on the International Psoriasis Council. In addition, Associate Professor Foley is on the Board of the Photomedicine Society.

Associate Professor Peter Foley graduated MBBS and BMedSc. from Monash University in 1987. His BMedSc. thesis was the first National Skin Cancer Survey. After obtaining an MD looking at the effects Vitamin D on the skin, Associate Professor Foley completed his dermatology training obtaining fellowship in 1997. Since that time he has consulted at Malvern. In addition, he attends the phototherapy, photodynamic therapy and biological therapy clinics at the Skin Health Institute and the dermatology investigation, biological therapy, photobiology and cutaneous lymphoma clinics at St Vincent’s Hospital, Melbourne where he is also Head of Dermatology Research.

Associate Professor Foley’s research activities include being a Principal Investigator for clinical trials, having been involved in over 70 trials for indications including psoriasis, eczema, seborrhoeic dermatitis, acne, rosacea, cutaneous lupus , hidradenitis suppurativa, tinea, actinic keratoses, nonmelanoma skin cancer and urticaria. He has an appointment as an Associate Professor in the Department of Medicine (Dermatology) at The University of Melbourne and is involved in medical student teaching. Currently he is Director of Research, and immediate Past-President of the Skin & Cancer Foundation (2008-2012), a tertiary referral centre with subspecialty dermatology clinics.

Associate Professor Foley has published widely and now has over 70 manuscripts in print.



Presentations by Peter Foley
Efficacy and Safety of Tildrakizumab in Australian Patients with Chronic Plaque Psoriasis in a Phase 3 Clinical Trial
Efficacy and Safety of Tildrakizumab in Australian Patients with Chronic Plaque Psoriasis in a Phase 3 Clinical Trial
Peter Foley, Lynda Spelman, Pablo Fernández-Peñas, Michael Freeman, Rod Sinclair
Characterization of Super Responders to Guselkumab Treatment in Moderate-to-Severe Psoriasis: Results from the VOYAGE 1 and 2 Clinical Trials
Characterization of Super Responders to Guselkumab Treatment in Moderate-to-Severe Psoriasis: Results from the VOYAGE 1 and 2 Clinical Trials
Kristian  Reich, Kenneth  B Gordon, Bruce Strober, Richard  G Langley, Michael  Song
An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI ≤15 versus >15
An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI ≤15 versus >15
Peter Foley, Melinda Gooderham, Kenneth Gordon, Diamant ThaçI, Renata Kisa,


No presentations found for today.